Advertisement

West Coast Sees Unusually Early Flu Spike Driven by New H1N1 Strain

Popular Posts

Advertisement
Close-up of a person holding a medical syringe prepared for vaccination against flu

Quick Read

  • Flu cases on the US West Coast are rising months earlier than the typical December ramp-up.
  • California's flu test positivity reached 9.65% by 10 October, compared to just over 1% in previous years.
  • Experts attribute the surge to a new mutation of the H1N1 influenza strain, which accounts for 242 of 300 lab-reported viruses.
  • The FDA approved 2026-27 flu vaccines in August, targeting H1N1, H3N2, and an influenza B virus.

Early Influenza Surge Recorded Across Western States

Influenza cases are climbing across the United States West Coast months ahead of the traditional schedule, according to data highlighted in an article published by the Guardian. While flu activity typically begins to ramp up in December and reaches its peak in February, public health laboratories have recorded higher-than-normal positive tests earlier in the autumn season.

Advertisement

Public health reporting shows that the unusual early momentum is concentrated in several western states. In California, influenza test positivity hovered slightly above 1% in early October during the past two seasons. However, state department of health data shows that the positivity rate reached 9.65% as of 10 October. A similar trend is evident in Utah, which recorded 242 influenza A cases as of 11 October, compared with just 10 cases at the same time last year, according to Germ Watch, an Intermountain Health database. Parts of central Oregon have also reported notable influenza A surges.

Strain Mutation and Vaccine Matching

Several experts have attributed the accelerated seasonal start to a new mutation of the influenza A strain H1N1, the virus responsible for the 2009 swine flu pandemic. Data from public health laboratories submitted to the Centers for Disease Control and Prevention (CDC) indicate that this specific H1N1 mutation has accounted for 242 out of 300 reported influenza viruses to date.

The Food and Drug Administration (FDA) approved the 2026-27 flu vaccines in August. These formulations target H1N1, H3N2—which was the dominant strain during the previous flu season—and one influenza B virus. Scott Hensley, a microbiologist at the University of Pennsylvania, noted via email that two of the three components in this year’s vaccine appear to be very well matched to circulating strains. Nevertheless, Hensley cautioned that the H1N1 mutation might affect antibody response in younger individuals, making early vaccination a prudent measure as the season gathers momentum.

Institutional Context and Public Health Guidance

The American Medical Association continues to recommend annual flu shots for all individuals aged six months and older, noting that the vaccines effectively reduce the risk of severe illness and hospitalization. Despite these clinical recommendations, the promotion of influenza immunizations has faced shifts under US health secretary Robert F Kennedy Jr, a long-standing vaccine critic who has overseen significant overhauls of established childhood immunization schedules. Reuters contributed reporting to the findings.

LATEST NEWS

Advertisement